OSI-906 (Linsitinib)

Catalog No.S1091

OSI-906 (Linsitinib) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Price Stock Quantity  
USD 190 In stock
USD 170 In stock
USD 270 In stock
USD 720 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

OSI-906 (Linsitinib) Chemical Structure

OSI-906 (Linsitinib) Chemical Structure
Molecular Weight: 421.49

Validation & Quality Control

3 customer reviews :

Quality Control & MSDS

Related Compound Libraries

IGF-1R Inhibitors with Unique Features

  • Pan IGF-1R Inhibitor

    GSK1904529A Dual IGF-1R/IR inhibitor, IC50=27 nM/25 nM.

  • Most Potent IGF-1R Inhibitor

    BMS-754807 IGF-1R, IC50=1.8 nM; InsR, IC50=1.7 nM.

  • IGF-1R Inhibitor in Clinical Trial

    BMS-754807 Phase II for Breast Cancer.

  • Newest IGF-1R Inhibitor

    PQ 401 Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Product Information

  • Compare IGF-1R Inhibitors
    Compare IGF-1R Products
  • Research Area
  • Inhibition Profile

Product Description

Biological Activity

Description OSI-906 (Linsitinib) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Targets IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
Abl [1]
(Cell-free assay)

 View  More

IC50 35 nM 75 nM 75 nM >10 μM
In vitro OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
A4-FukNX:0[5R2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFr4eJNKSzVyPUCuNFI5ODZizszNMUnTRW5ITVJ?
KS-1M17ndmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGjaTpJKSzVyPUCuNFM5OzVizszNNWixU49TW0GQR1XS
TE-11MkXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTBwMEe4NlIh|ryPNHXaZYlUSU6JRWK=
EW-1NF\Ne21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{LkbWlEPTB;MD6wPFU5PSEQvF2=NV;ue2Y{W0GQR1XS
HMV-IIMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTBwMEi4OFYh|ryPMX7TRW5ITVJ?
COLO-205NIDUfFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1rBfGlEPTB;MD6xNFQ2PCEQvF2=M17aVHNCVkeHUh?=
ES1M1Pne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF3NNplKSzVyPUCuNVA3QTZizszNNYjyNWFxW0GQR1XS
GDM-1MnvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF\oU2ZKSzVyPUCuNVM3PzJizszNNY\2Z2wxW0GQR1XS
ML-2NX\IfYpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTBwMUW4PVYh|ryPNEXnW3BUSU6JRWK=
Saos-2M4HvT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV\ZO4hPUUN3ME2wMlE3PTJ4IN88US=>NF3BSI5USU6JRWK=
NCI-H1355NHOyUY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVPJR|UxRTBwMUixN|Uh|ryPM2fTOHNCVkeHUh?=
G-401M2PG[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{\BTWlEPTB;MD6xPFI{KM7:TR?=M1j1ZXNCVkeHUh?=
EW-16NUnZeIxXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFiyfpVKSzVyPUCuNVg4PzdizszNNGC5UoNUSU6JRWK=
EW-7M{HL[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUHXSmtMUUN3ME2wMlE5QDhzIN88US=>MUHTRW5ITVJ?
NCI-H727NEGxNHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF3XOY1KSzVyPUCuNVk4QTRizszNM2rPZnNCVkeHUh?=
LCLC-97TM1MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnPqTWM2OD1yLkKwPVU2KM7:TR?=NIHMdYVUSU6JRWK=
NCI-H650M3zDeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVLJR|UxRTBwMkGzPFQh|ryPMl7ZV2FPT0WU
NCI-H2122NWrzcFRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1TvT2lEPTB;MD6yN|I6QSEQvF2=NH\aRm9USU6JRWK=
SK-N-DZMXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXZTWM2OD1yLkKzOlk5KM7:TR?=NYi4OoI3W0GQR1XS
HT-29NXT3W4N3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXkR|RwUUN3ME2wMlI1OjR6IN88US=>NXPjdWtYW0GQR1XS
LB771-HNCNWD2VpBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUDXV5M4UUN3ME2wMlI2QTF3IN88US=>NF\ZWlFUSU6JRWK=
HT-144NUfBNHhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTBwMk[xPVEh|ryPNYDwVGY6W0GQR1XS
LAN-6NWnUe3FoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2XNRmlEPTB;MD6yOlM1QCEQvF2=MknoV2FPT0WU
EW-18MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3rzWGlEPTB;MD6yO|AxOSEQvF2=NIHw[4RUSU6JRWK=
LS-1034NYLGcm5kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4PoWWlEPTB;MD6yO|E{OiEQvF2=NGTGeppUSU6JRWK=
EW-11NFeweodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4DCR2lEPTB;MD6yPFQ{OiEQvF2=M2WwenNCVkeHUh?=
SNU-C1MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NInJTYVKSzVyPUCuNlk{OTNizszNNEn1cZFUSU6JRWK=
RS4-11NU\MTWlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{TaR2lEPTB;MD6zN|c2QCEQvF2=M2HZOXNCVkeHUh?=
ES4MlvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRTBwNEGwN|gh|ryPMl7qV2FPT0WU
COLO-320-HSRMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2DnOGlEPTB;MD60NVM3QCEQvF2=NIjGdohUSU6JRWK=
NB10MnW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRTBwNEW0N|ch|ryPMYjTRW5ITVJ?
BFTC-905MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1zJNWlEPTB;MD60Olc2QCEQvF2=M3HvRnNCVkeHUh?=
A375MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEDhXodKSzVyPUCuOFc3OTdizszNMV7TRW5ITVJ?
SJRH30MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIDOfYpKSzVyPUCuOVA5OjJizszNNX3Qc3lMW0GQR1XS
NOS-1Ml\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXtRm5KSzVyPUCuOVIzPjdizszNNEDU[YxUSU6JRWK=
SIG-M5MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGi2bmdKSzVyPUCuOVM2PTdizszNMnnTV2FPT0WU
DOKMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnHpTWM2OD1yLkW1OkDPxE1?NWX6c4pMW0GQR1XS
NB69MnXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFPL[5JKSzVyPUCuOVgzPTdizszNMXHTRW5ITVJ?
SK-NEP-1NVPxO3ViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTBwNkCyN|Yh|ryPMl\RV2FPT0WU
SK-MM-2MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkT4TWM2OD1yLk[1OFkyKM7:TR?=NGm1W3RUSU6JRWK=
NCI-H358M1Hrfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGHvTXJKSzVyPUCuOlcxQDJizszNM2q4OXNCVkeHUh?=
RH-1MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnS4TWM2OD1yLke0PFU6KM7:TR?=M4f0VXNCVkeHUh?=
NH-12M3PmSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoTlTWM2OD1yLke2NFQ3KM7:TR?=NHj6PJdUSU6JRWK=
TE-12NUDxb5dXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFuxcXBKSzVyPUCuO|Y1QDZizszNNVP1WIZUW0GQR1XS
COLO-668NUjGSIpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE\ZRoZKSzVyPUCuPFQ3PjZizszNMmGyV2FPT0WU
PANC-08-13NUnafnBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlG2TWM2OD1yLki2N|c4KM7:TR?=MmfiV2FPT0WU
HCC2998M{PiNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXjJR|UxRTBwOEiyOlMh|ryPNYfod|NtW0GQR1XS
ABC-1M13FVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVvubYF2UUN3ME2wMlkxOzV{IN88US=>NYG4cZZlW0GQR1XS
ES6NWq5UVNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4fmN2lEPTB;MD65NVA3PiEQvF2=NVzCUoN4W0GQR1XS
SNU-387MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkjpTWM2OD1yLkm5N|k{KM7:TR?=MmDHV2FPT0WU
CMKNWLUWYk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHX1S2lKSzVyPUCuPVk6OjlizszNNVf4fVBnW0GQR1XS
SJSA-1NFG2co5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFfwc4FKSzVyPUGuNFM3PTNizszNMkHVV2FPT0WU
SIMAMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX7JR|UxRTFwME[4NlUh|ryPMlv0V2FPT0WU
ES3MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF3LSY9KSzVyPUGuNVIzQTdizszNNVXOfXIzW0GQR1XS
IGROV-1M1vqbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVvJR|UxRTFwMUW0OFQh|ryPMnrFV2FPT0WU
MEL-JUSOMmnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVzmXXpSUUN3ME2xMlE2PzV7IN88US=>NVTUPVJwW0GQR1XS
T84NVK4R4lyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHicXJrUUN3ME2xMlIxQTF2IN88US=>MWTTRW5ITVJ?
CAL-85-1MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NI[5bGRKSzVyPUGuNlMyOzhizszNMlzWV2FPT0WU
RDMn\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{nlU2lEPTB;MT6yOlQ2PSEQvF2=M1jXXHNCVkeHUh?=
TE-8M1y3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{e1SGlEPTB;MT6zNVQ3OiEQvF2=M{nCZnNCVkeHUh?=
L-363MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjwTWM2OD1zLkO0NlA5KM7:TR?=MV7TRW5ITVJ?
EKVXMnvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2XNUWlEPTB;MT6zOFU3QCEQvF2=M1XU[XNCVkeHUh?=
SK-MEL-3M{HoN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWXoVm9nUUN3ME2xMlQ5PTV4IN88US=>NHvEbXRUSU6JRWK=
TGBC24TKBNFvlOYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTFwNUCxPVMh|ryPMmq3V2FPT0WU
NCI-H1770M4OyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTFwNUGxNVMh|ryPM{XsZXNCVkeHUh?=
HuH-7MlrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3rEc2lEPTB;MT62NFA6QCEQvF2=MX;TRW5ITVJ?
HL-60NWfLXm5WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXTxOoVIUUN3ME2xMlY3QTJ6IN88US=>NVrJU5lbW0GQR1XS
TE-1NVPZe45zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MofyTWM2OD1zLkewPVQ2KM7:TR?=Ml\DV2FPT0WU
LC-2-adMoDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTFwN{O4PFch|ryPMmLRV2FPT0WU
LB647-SCLCMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmLZTWM2OD1zLke2OVg{KM7:TR?=NGS1cZpUSU6JRWK=
NCI-H2171NWfacFRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1O1VGlEPTB;MT63O|cyPiEQvF2=MmXjV2FPT0WU
SK-PN-DWM{LBTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1HjV2lEPTB;MT65NVI6QCEQvF2=NGj6NJBUSU6JRWK=
MC-IXCNVT4ZphXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2Cze2lEPTB;MT65PFk5KM7:TR?=MoPpV2FPT0WU
LS-513M13JTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1fWUGlEPTB;Mj6wOVMxPSEQvF2=NWj3dnBoW0GQR1XS
EW-3NHnLV5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn3vTWM2OD1{LkC5PFQ1KM7:TR?=NGr6cYZUSU6JRWK=
OPM-2MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NILqN5pKSzVyPUKuNVAzKM7:TR?=MWnTRW5ITVJ?
LP-1M4TlSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTJwMkW4NFch|ryPNI\U[2pUSU6JRWK=
LU-134-ANIK0b4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NW\zZoxiUUN3ME2yMlI4PyEQvF2=NWWwU|ZZW0GQR1XS
CP66-MELMme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4nXRmlEPTB;Mj6yPVAyPCEQvF2=M370VnNCVkeHUh?=
HCC1143NX\uTY9FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEDGfWhKSzVyPUKuOFU{PjhizszNM{L2bXNCVkeHUh?=
LOXIMVIMo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYTFPJE4UUN3ME2yMlYxOjFizszNMmLlV2FPT0WU
TE-10NXrRWnBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjKNnR6UUN3ME2yMlcxQDN6IN88US=>NUHQWXNSW0GQR1XS
NCI-H1882MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEOxT4dKSzVyPUKuO|UzOjdizszNMlTFV2FPT0WU
CHP-126M4LsWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUnJR|UxRTJwN{[zNVch|ryPNF:1NJZUSU6JRWK=
NCI-H1623NH2zVpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTJwOUKwNlQh|ryPMUnTRW5ITVJ?
GB-1MnGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{L1SmlEPTB;Mj65N|QxPCEQvF2=NYXKb5k{W0GQR1XS
RCC10RGBMmH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkPKTWM2OD1{Lkm1NlgyKM7:TR?=M133ZXNCVkeHUh?=
NCI-H2141M{C1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTJwOU[4PVYh|ryPNWjtPIxkW0GQR1XS
GI-ME-NM37hWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2fKT2lEPTB;Mz6wNFU3PSEQvF2=NGjlXlVUSU6JRWK=
NCI-H526MmfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTNwMESwPFUh|ryPMXXTRW5ITVJ?
NCI-H747MnjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYjKbYo5UUN3ME2zMlA1QTl{IN88US=>MUTTRW5ITVJ?
SNU-423Mn\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYrnRnl1UUN3ME2zMlIxOzF|IN88US=>MknVV2FPT0WU
A427NV7K[FFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MorZTWM2OD1|LkK1Olk6KM7:TR?=NV3lbVdGW0GQR1XS
CAL-12TNFvNb4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWLuc492UUN3ME2zMlQxPzF|IN88US=>MYPTRW5ITVJ?
LU-99AM1XsXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXXJR|UxRTNwNEexNFUh|ryPMlXMV2FPT0WU
MS-1MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWi2VXVvUUN3ME2zMlU{PDJ7IN88US=>MmOzV2FPT0WU
SK-LU-1MorQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlzrTWM2OD1|Lke2Nlk2KM7:TR?=MYTTRW5ITVJ?
SW837NGXoO4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1:2bmlEPTB;Mz63OlM{OyEQvF2=MlO4V2FPT0WU
ES8NE\sdnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1WwNWlEPTB;Mz64N|g4PyEQvF2=MmfCV2FPT0WU
MZ2-MELMn:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFjIdXpKSzVyPUOuPVIxQDZizszNM1vibnNCVkeHUh?=
TGWNUPlem81T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFfqNHBKSzVyPUSuNFE{OTFizszNM1;BOHNCVkeHUh?=
GP5dNXqxOnlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn3oTWM2OD12LkC1N|YzKM7:TR?=NEi3VJlUSU6JRWK=
BB49-HNCM3zaSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1XXZ2lEPTB;ND6xOVIyOyEQvF2=MYPTRW5ITVJ?
NB13MkfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTRwMk[4PFch|ryPNYjLRZVmW0GQR1XS
NTERA-S-cl-D1NWjSbmFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTRwMki2NVUh|ryPMljPV2FPT0WU
NCI-H1648NHrZS4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUXVVWJwUUN3ME20MlI6QDF7IN88US=>NXm2Zlk3W0GQR1XS
LCLC-103HNGjDdXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGnvT4xKSzVyPUSuN|IyQTVizszNM4PicXNCVkeHUh?=
LS-411NNF7ZSXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2rmSmlEPTB;ND60OFg5PSEQvF2=M1j4enNCVkeHUh?=
NCI-H1092MmHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTRwNEW2PFch|ryPMmTzV2FPT0WU
PANC-10-05MnHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVTwXpIxUUN3ME20MlY6QDRizszNM1vjenNCVkeHUh?=
DK-MGMlL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUHvdFRFUUN3ME20MlgxQTN|IN88US=>MWDTRW5ITVJ?
OVCAR-5MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NInRbWlKSzVyPUSuPFEzOjZizszNNVnaXWZMW0GQR1XS
CAL-39NUPRbFl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTRwOEe2O{DPxE1?MnXJV2FPT0WU
TE-441-TM2D0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH;NTI5KSzVyPUSuPVA2OzdizszNMnXCV2FPT0WU
MOLT-16NIHncWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NILzOI1KSzVyPUSuPVUzPTNizszNM{nCRnNCVkeHUh?=
MCF7MkK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGHEeHZKSzVyPUWuNVQ2OTdizszNM{\OSnNCVkeHUh?=
CAPAN-1MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX7nXZpUUUN3ME21MlI2PzB5IN88US=>NHfDZopUSU6JRWK=
PSN1M1Tldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLBZVdKUUN3ME21MlI4OjN3IN88US=>MVLTRW5ITVJ?
NCI-H292NEXQVG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTVwM{CwOFQh|ryPMXjTRW5ITVJ?
CPC-NMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWLMd4pJUUN3ME21MlM6PDF7IN88US=>MYHTRW5ITVJ?
DoTc2-4510MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1nZOmlEPTB;NT60OVM4OSEQvF2=Ml:2V2FPT0WU
LB1047-RCCM4XEOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnjtTWM2OD13LkW1PVM{KM7:TR?=M1niZXNCVkeHUh?=
MHH-ES-1MlLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnLZTWM2OD13LkW5PVA4KM7:TR?=NFLPeo1USU6JRWK=
NMC-G1MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF7GTFZKSzVyPUWuO|AzOjdizszNM4GwUnNCVkeHUh?=
SW1710MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDZOppKSzVyPUWuO|Q4PTFizszNMVHTRW5ITVJ?
YAPCM1LhOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHTENIlKSzVyPUWuO|YzODFizszNNU\nNYJCW0GQR1XS
22RV1MmrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXfGW5UzUUN3ME21MlgxODF7IN88US=>MUjTRW5ITVJ?
COLO-679NUDjbGozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkP4TWM2OD13Lki4PVQ5KM7:TR?=NH7sdmpUSU6JRWK=
TCCSUPNGPOZ3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLhN2RKSzVyPUWuPVMzPTlizszNMWnTRW5ITVJ?
C2BBe1NUO3UFFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYHHepI6UUN3ME21Mlk{QTdizszNNHfTN49USU6JRWK=
TE-15MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTZwME[2NFUh|ryPNV7y[GQ2W0GQR1XS
SCLC-21HNWfY[pZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVPQcW9xUUN3ME22MlExQDR|IN88US=>MUHTRW5ITVJ?
EoL-1-cellNHn1cJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFfGRmNKSzVyPU[uNVY2PjNizszNM3jOe3NCVkeHUh?=
NKM-1NHzBUJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkTETWM2OD14LkG2O|Eh|ryPMnq3V2FPT0WU
NCI-H1304M1y1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUHMeG9xUUN3ME22MlI4PDJ6IN88US=>MU\TRW5ITVJ?
NB6NH60U5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVr6UZd4UUN3ME22MlI6PjJ{IN88US=>MWrTRW5ITVJ?
NALM-6NWjySZJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnvZTWM2OD14LkOzNlMh|ryPNEXFeGxUSU6JRWK=
NCI-H522M33iW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTZwM{OzNFYh|ryPMVXTRW5ITVJ?
MV-4-11NEH5O3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV34XJJ{UUN3ME22MlM4ODd7IN88US=>MnLzV2FPT0WU
LB2241-RCCM1fPT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4rFfWlEPTB;Nj6zPFY3PyEQvF2=Mk\WV2FPT0WU
NCI-H1417NIm2NIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{m2[WlEPTB;Nj60NFg1PyEQvF2=NFrzfJlUSU6JRWK=
HT-1197NEXTPItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXHqeHZyUUN3ME22MlU4OTJ{IN88US=>MkPkV2FPT0WU
P30-OHKMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEjQ[5lKSzVyPU[uOlI4PyEQvF2=M1vucnNCVkeHUh?=
ALL-PONVj2OHBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{P4e2lEPTB;Nj63NVkyPiEQvF2=NFTWfIxUSU6JRWK=
OVCAR-4M1iwUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTZwN{W0NFUh|ryPMlzEV2FPT0WU
HCC2157MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVjqSml3UUN3ME22Mlc4PDd3IN88US=>NYS4UJNyW0GQR1XS
NCI-H838MnnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHHnVYFKSzVyPU[uPVY1QSEQvF2=MUnTRW5ITVJ?
NCI-H1299MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2joSmlEPTB;Nj65O|A6KM7:TR?=MkTRV2FPT0WU
SW954NIDHeGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkHyTWM2OD15LkKwNFY5KM7:TR?=NHLhTZFUSU6JRWK=
NCI-H441NEXFcGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4HVdmlEPTB;Nz6zOFA3PSEQvF2=MVfTRW5ITVJ?
SK-MEL-2MoO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRTdwNEizO|Mh|ryPNHj6TYZUSU6JRWK=
KARPAS-45M4G1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXzn[HpZUUN3ME23MlY2QTJ7IN88US=>NVrDfm96W0GQR1XS
CAL-54MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTdwOEK5O|ch|ryPMn\1V2FPT0WU
KYSE-180M1XwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTdwOEi5OFEh|ryPM{LQPXNCVkeHUh?=
NCI-H187M33Odmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRTdwOUW5OFch|ryPNF\G[HdUSU6JRWK=
RT-112NGnqPYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NG\yZoNKSzVyPUiuNFk3PzdizszNNUnH[2NbW0GQR1XS
NCI-H1437MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3LyS2lEPTB;OD6wPVc6PSEQvF2=M{DKWnNCVkeHUh?=
SNU-449NXfaO|l{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFu4bnZKSzVyPUiuNlgzPzJizszNMnjOV2FPT0WU
HCC1187M4PtXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRThwMkmzPVEh|ryPNVzEb|BGW0GQR1XS
NCI-H2030MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUT5TnVIUUN3ME24MlM4PzF2IN88US=>NYDBfm91W0GQR1XS
HuO-3N1MmDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInDcm1KSzVyPUiuN|c5PDRizszNNVnWNFRFW0GQR1XS
COLO-792M2LXPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDyfnlZUUN3ME24MlQyPTJ5IN88US=>MYrTRW5ITVJ?
MIA-PaCa-2MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWHKNo9GUUN3ME24Mlg2PTB6IN88US=>MYPTRW5ITVJ?
SK-N-FINU\aXWhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXzJR|UxRTlwMESyOUDPxE1?NWKzV2tOW0GQR1XS
MMAC-SFNETIdGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoS2TWM2OD17LkC5O|UyKM7:TR?=NVHYN3FLW0GQR1XS
NCI-H28MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4LCRmlEPTB;OT6xNFQ3QSEQvF2=MVPTRW5ITVJ?
ETK-1NISx[mVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlGyTWM2OD17LkK5PVc1KM7:TR?=NWT2dXN{W0GQR1XS
NCI-H1993MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTlwNESyOlEh|ryPNUnCSXFyW0GQR1XS
no-11M{LQSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWfJR|UxRTlwNEexNkDPxE1?NH;GN4dUSU6JRWK=
ChaGo-K-1NEjnXm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4\pU2lEPTB;OT61NVU5OyEQvF2=NXTLTJBKW0GQR1XS
NCCITMmT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn3iTWM2OD17LkWzNVY6KM7:TR?=M3XCZXNCVkeHUh?=
SASM1TYcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXr3OIZWUUN3ME2xNE4zPDhizszNMUjTRW5ITVJ?
A673MlzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4\rOWlEPTB;MUCuN|cxPCEQvF2=NIfDeZpUSU6JRWK=
NCI-H1522NXjJRWNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYr6SmZFUUN3ME2xNE4{PzB5IN88US=>NITi[IxUSU6JRWK=
NCI-H810NHHUR4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mlr2TWM2OD1zMD6zPVA4KM7:TR?=M2LHdnNCVkeHUh?=
IST-MES1NGHMZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHPwWlBKSzVyPUGwMlQ2PjRizszNMVXTRW5ITVJ?
GR-STMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXwTWM2OD1zMD61NFI1KM7:TR?=NWrSO5Y6W0GQR1XS
SUP-T1MoCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3mxPWlEPTB;MUCuO|MyPyEQvF2=NGPuTW1USU6JRWK=
NB5NX;hNndIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGPKZ5JKSzVyPUGwMlkxOjJizszNNUn5dHpVW0GQR1XS
MZ1-PCNIrGOm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlHuTWM2OD1zMD65OVcyKM7:TR?=M2r0PHNCVkeHUh?=
SK-CO-1NWrRNHZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFHicWJKSzVyPUGwMlk6OzFizszNM1LlNnNCVkeHUh?=
Capan-2NVPFdo46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX6wcGs4UUN3ME2xNU4{OTl6IN88US=>NU\vUYJPW0GQR1XS
697NVX5S2tST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUnoWo5SUUN3ME2xNU43PzV5IN88US=>M2\IeXNCVkeHUh?=
REHMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2njSWlEPTB;MUGuO|Q2OSEQvF2=NHTqeZVUSU6JRWK=
GI-1Mn71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUHVXmVMUUN3ME2xNU45PjF3IN88US=>Ml3VV2FPT0WU
BB65-RCCMnTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnfOTWM2OD1zMj6wPVE3KM7:TR?=NFz0eG5USU6JRWK=
NCI-H1651MlPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXn0e3JpUUN3ME2xNk4zPDd6IN88US=>NGLGSJVUSU6JRWK=
NCI-H1618NH[1c3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUHvTm1mUUN3ME2xNk4{QTd4IN88US=>MmHBV2FPT0WU
NCI-H2081MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3vVXWlEPTB;MUKuOlE1OSEQvF2=M2XTWnNCVkeHUh?=
GCIYNH7YXJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlHpTWM2OD1zMj63NlE{KM7:TR?=MXnTRW5ITVJ?
NYNVjQTVB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVPJR|UxRTF|LkC2OFMh|ryPMkWwV2FPT0WU
PANC-03-27NX3weWt7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTF|LkC4NFch|ryPMkLFV2FPT0WU
BHYM176cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoHsTWM2OD1zMz6yNVIyKM7:TR?=M1LxRXNCVkeHUh?=
SK-OV-3NFixepBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkXnTWM2OD1zMz6zO|Y{KM7:TR?=MmP4V2FPT0WU
5637NF\NO|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkDETWM2OD1zMz63O|U6KM7:TR?=NEXjTG1USU6JRWK=
LC-1FM{H4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MorJTWM2OD1zND6wN|U3KM7:TR?=MVvTRW5ITVJ?
SNB75M2e2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTF2LkCzPFMh|ryPM2Dj[XNCVkeHUh?=
CHP-212M3nTbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmXnTWM2OD1zND6wOFY1KM7:TR?=MVrTRW5ITVJ?
HT-1376NInQZpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHf0fXVKSzVyPUG0MlEyOjZizszNMYHTRW5ITVJ?
MONO-MAC-6NHzkd4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTF2LkG1NFIh|ryPMX\TRW5ITVJ?
CA46MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmDETWM2OD1zND6xPFI4KM7:TR?=MlGzV2FPT0WU
SCC-15NIqyR|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4ftOGlEPTB;MUSuOVU5OyEQvF2=NFfKOFRUSU6JRWK=
ATN-1M4X6[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYjJR|UxRTF2Lk[2Nlch|ryPM4nHSXNCVkeHUh?=
NCI-H2405MnXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEfUR4lKSzVyPUG0MlgyPTdizszNNWW4dIVsW0GQR1XS
NCI-H716NWe2WlkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYfmNm1UUUN3ME2xOE45PDl|IN88US=>NVWxO45KW0GQR1XS
SW620MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4jZU2lEPTB;MUSuPVAyPCEQvF2=NYHFUpZzW0GQR1XS
NCI-H226M2\pdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFjHOYlKSzVyPUG0MlkxQDVizszNM3;JTXNCVkeHUh?=
SW962NXr5fmFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH62d4lKSzVyPUG0Mlk1OzJizszNNX\QWIppW0GQR1XS
KYSE-150MnXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnjkTWM2OD1zND65OVUh|ryPMlzzV2FPT0WU
OCUB-MMXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTF2Lkm4PFMh|ryPMnm2V2FPT0WU
ES7Mle5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV:5UHdpUUN3ME2xOU4xQTh2IN88US=>MVHTRW5ITVJ?
SW1463NELhUodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4HiOGlEPTB;MUWuOFIzOyEQvF2=NW\vOGRrW0GQR1XS
CAKI-1NXvrW3NIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWH1ToRRUUN3ME2xOU42OzR4IN88US=>NX;M[5VqW0GQR1XS
MKN28M1K1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHnoNnhKSzVyPUG1MlU1PzlizszNNYL4VZRLW0GQR1XS
SW13M1\LTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2nQbmlEPTB;MUWuOlE5KM7:TR?=MnPUV2FPT0WU
A3-KAWNHLJbZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFfMc5hKSzVyPUG1Mlk3QTdizszNNYjUWpl7W0GQR1XS
LU-65NYfScVdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYew[GFkUUN3ME2xOU46PzZ6IN88US=>MV3TRW5ITVJ?
Calu-1M{nXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnPRTWM2OD1zNj6wN|Y5KM7:TR?=M3i2fXNCVkeHUh?=
ST486NYrIdpl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTF4LkC0N|Eh|ryPM2TDWnNCVkeHUh?=
BB30-HNCNIfQc4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1\DeWlEPTB;MU[uNVI1PiEQvF2=NF70dYtUSU6JRWK=
EGI-1MnvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkfxTWM2OD1zNj60OFYh|ryPNIXhN2hUSU6JRWK=
SH-4NEDFTmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnrJTWM2OD1zNj60O|MyKM7:TR?=NWO2d|VEW0GQR1XS
MN-60NFvvXHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml3STWM2OD1zNz6yNlk4KM7:TR?=NUTwe2czW0GQR1XS
MPP-89M3LrVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVXJR|UxRTF5LkK0OVkh|ryPMkTFV2FPT0WU
A2780M17ofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYX3[oQ1UUN3ME2xO{41OTN7IN88US=>M{f6bnNCVkeHUh?=
DaoyM1nDUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{XjSGlEPTB;MUeuOFY6PSEQvF2=NH36S3BUSU6JRWK=
NCI-H2126NUTKV4hiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTF5LkS3O|Eh|ryPNXPnV2ZmW0GQR1XS
NCI-H1563MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXf5cZcxUUN3ME2xO{41QTF5IN88US=>MnPZV2FPT0WU
8-MG-BANGLnZnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn7GTWM2OD1zNz62OlQ5KM7:TR?=NX\jXXlvW0GQR1XS
786-0NF7yWVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmDoTWM2OD1zNz64N|U{KM7:TR?=M2PmSXNCVkeHUh?=
AM-38MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkjDTWM2OD1zNz65N|A3KM7:TR?=M4\NVXNCVkeHUh?=
COLO-824MlLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUfwfVg1UUN3ME2xPE41PDN4IN88US=>MUfTRW5ITVJ?
SK-MEL-30NFLYNY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXPiOplXUUN3ME2xPE42ODh{IN88US=>NHXw[5ZUSU6JRWK=
CESSM{XJ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHjofFBKSzVyPUG4Mlc3ODlizszNNFqzUW1USU6JRWK=
BL-70MnPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2H1dWlEPTB;MUiuPFE2PiEQvF2=M3u3PHNCVkeHUh?=
NCI-H2170M2r3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGi1enhKSzVyPUG4MlkyPzlizszNMY\TRW5ITVJ?
HT-3NEj3TpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTF6Lkm4N{DPxE1?MV\TRW5ITVJ?
BOKUNVnXOGN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIH6NpBKSzVyPUG5MlA{QDFizszNNWm0W2xkW0GQR1XS
HPAF-IINHPwblBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTF7LkOwNVUh|ryPNXHzcHl[W0GQR1XS
KGNMlPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{GxVmlEPTB;MUmuOFc3PSEQvF2=M3jhTHNCVkeHUh?=
MC-CARMnjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYi0bnJGUUN3ME2xPU43OzF|IN88US=>NEHzbZhUSU6JRWK=
BHT-101MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnrmTWM2OD1zOT63O|ch|ryPMUnTRW5ITVJ?
SW1783NXTOUGI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnf0TWM2OD1zOT63PFA3KM7:TR?=MkLzV2FPT0WU
KP-N-YNMoLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1rSOWlEPTB;MkCuNFI3OiEQvF2=MkW3V2FPT0WU
LU-165NGiyU3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlnFTWM2OD1{MD61OVcyKM7:TR?=NYrmNGNVW0GQR1XS
GOTONYmyNW5GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1XhVWlEPTB;MkCuOlQ2OSEQvF2=NFjKZotUSU6JRWK=
EFM-19MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWDjXFdDUUN3ME2yNU4xPzF4IN88US=>NV3FRWp5W0GQR1XS
CTV-1MnfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIqwO3lKSzVyPUKxMlExPTRizszNNFvnPG9USU6JRWK=
HELMknZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVXJR|UxRTJzLkSyNVYh|ryPMYrTRW5ITVJ?
SNU-C2BM3XHcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTJzLkSyOkDPxE1?MVLTRW5ITVJ?
ECC4MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkDGTWM2OD1{MT63NFch|ryPNVWycFFWW0GQR1XS
NEC8MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmLDTWM2OD1{MT64N|Y5KM7:TR?=MWfTRW5ITVJ?
KMOE-2MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWPQOVJ[UUN3ME2yNU45QTJzIN88US=>MkPRV2FPT0WU
NCI-H524NGG3[mxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXnJR|UxRTJ{LkC4NFgh|ryPM{X5bXNCVkeHUh?=
WSU-NHLM2j4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnjSTWM2OD1{Mj6xOVc4KM7:TR?=M4TjUHNCVkeHUh?=
SF126MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTJ{LkK0Olkh|ryPNWLET4NnW0GQR1XS
HOP-92NH[zUGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWPVT|JSUUN3ME2yNk4{OTZ5IN88US=>NUi1Z403W0GQR1XS
CTB-1NFjTWnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnPiTWM2OD1{Mj60Olc4KM7:TR?=MkG3V2FPT0WU
KYSE-270M{TBTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn3pTWM2OD1{Mj65N|U4KM7:TR?=NHnhN4JUSU6JRWK=
SK-MEL-24MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3nK[GlEPTB;MkOuNVg4KM7:TR?=MVrTRW5ITVJ?
Calu-3MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYDJR|UxRTJ|LkKxNlgh|ryPMXnTRW5ITVJ?
GAMGMor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVHJR|UxRTJ|LkKzOlch|ryPNYHZZ3liW0GQR1XS
SW1573Ml3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEXqW|lKSzVyPUKzMlc1OTVizszNNYrCbmdGW0GQR1XS
MHH-NB-11MoLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUfJR|UxRTJ2LkCxPVQh|ryPMYnTRW5ITVJ?
TK10MkHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHnoXZVKSzVyPUK0MlUxOTNizszNNV7Q[3hCW0GQR1XS
LB373-MEL-DMmTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUjLV2d{UUN3ME2yOE43ODZ2IN88US=>NEHWc2pUSU6JRWK=
KALS-1MoLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MofhTWM2OD1{ND63N|I4KM7:TR?=MUfTRW5ITVJ?
HUTU-80M3n5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHe0[ohKSzVyPUK1MlgxOzJizszNNWnwdFV2W0GQR1XS
HuP-T3MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYHJR|UxRTJ4LkG2O|Qh|ryPM3XIW3NCVkeHUh?=
OE19MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIOwZYpKSzVyPUK2MlIyPTNizszNM3faWXNCVkeHUh?=
J82NHTXTmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWrJR|UxRTJ4LkK0O|Eh|ryPMV\TRW5ITVJ?
DU-4475MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlHsTWM2OD1{Nj6zPFE6KM7:TR?=NHXZ[JVUSU6JRWK=
DMS-53Mn;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTJ4LkWxN|gh|ryPNVHvbZdLW0GQR1XS
COLO-741MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1HLc2lEPTB;Mk[uPFM1PCEQvF2=M13WPXNCVkeHUh?=
SW48NGK3NIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1fvVWlEPTB;Mk[uPFgzKM7:TR?=M1;YVXNCVkeHUh?=
IGR-1NYiydFI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRTJ4LkmzN|Qh|ryPNVjtb|ByW0GQR1XS
639-VMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH\nWoFKSzVyPUK3MlAzPDVizszNM{K1bnNCVkeHUh?=
LK-2Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmjlTWM2OD1{Nz60NVQyKM7:TR?=MnLpV2FPT0WU
NCI-H2347M3W3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVfJR|UxRTJ5Lkm2PVkh|ryPM3zOe3NCVkeHUh?=
NCI-H2228M{XqNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vISmlEPTB;MkiuNFkxPSEQvF2=Ml\QV2FPT0WU
LS-123NVH3O4F{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVjRUXVuUUN3ME2yPE4yOjZ{IN88US=>MU\TRW5ITVJ?
U031MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGHuZodKSzVyPUK4MlI2OiEQvF2=M{DafnNCVkeHUh?=
NCI-H1792Mn;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4jNSmlEPTB;MkiuOFczOSEQvF2=NIjIdoZUSU6JRWK=
NCI-H2087NWnYcnU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGnt[XhKSzVyPUK4Mlc2PTJizszNMkjiV2FPT0WU
NCI-H2342NFj5RYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmL1TWM2OD1{OT61NlA5KM7:TR?=M3XBNHNCVkeHUh?=
SW626MoPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2KxeGlEPTB;MkmuO|U3KM7:TR?=M4G0Z3NCVkeHUh?=
LB2518-MELMlX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYDSR2dqUUN3ME2yPU45OTVizszNMonjV2FPT0WU
RXF393NHLxVY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXG3ZYlCUUN3ME2zNE4xQTV{IN88US=>NWTXPVZoW0GQR1XS
LC4-1NHvWS3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHe3TZRKSzVyPUOwMlMxQTJizszNMlLyV2FPT0WU
NCI-H1694M1\u[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3fhSGlEPTB;M{CuOlYzPCEQvF2=MkDWV2FPT0WU
K5MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH\RfVVKSzVyPUOwMlk4ODJizszNMlT4V2FPT0WU
HDLM-2MlLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG\KUVVKSzVyPUOwMlk4OjVizszNMkDrV2FPT0WU
BCPAPNYPabm9yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWKxc5U5UUN3ME2zNU45Ozd7IN88US=>NXfoeWJWW0GQR1XS
BC-3NX3y[mFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV;JR|UxRTN{LkG0NFMh|ryPMVPTRW5ITVJ?
LB996-RCCNVr3R4tIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFTtNmtKSzVyPUOyMlI{PThizszNNUnLfVVMW0GQR1XS
NCI-H2009MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIXNNVBKSzVyPUOyMlQ6QDFizszNNUfWWFB[W0GQR1XS
HTC-C3M{LRcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlP3TWM2OD1|Mz63OVE6KM7:TR?=M{nzZXNCVkeHUh?=
LAMA-84M{S4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkDnTWM2OD1|ND60OFA4KM7:TR?=NWnofItNW0GQR1XS
CCRF-CEMM2rNXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;tTWM2OD1|ND61O|E2KM7:TR?=MYPTRW5ITVJ?
AN3-CANYKwc4ZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTN3LkC1Olgh|ryPMXXTRW5ITVJ?
NCI-H1734NIK1XW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWC4OIw5UUN3ME2zOU4zPTZzIN88US=>NWWyR4p3W0GQR1XS
Ca-SkiMl3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVHJR|UxRTN3LkSxNFEh|ryPNIfacIRUSU6JRWK=
U-266M3rrR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTN3Lk[xNVQh|ryPM1f1XXNCVkeHUh?=
SBC-5MlfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M17kZWlEPTB;M{WuO|c5OSEQvF2=M2jKV3NCVkeHUh?=
GT3TKBMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1Lid2lEPTB;M{euNVE2KM7:TR?=MWLTRW5ITVJ?
MDA-MB-175-VIIMmTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnPhTWM2OD1|Nz6yNlQ5KM7:TR?=MYXTRW5ITVJ?
PFSK-1NILXSG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIL2T3dKSzVyPUO3MlI1OzVizszNMn3CV2FPT0WU
IMR-5NFHjTXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHPKTlBKSzVyPUO3MlI1QDdizszNM3Xae3NCVkeHUh?=
DaudiMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGPpUoZKSzVyPUO3MlM2QTdizszNNX3VZWc6W0GQR1XS
A498MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWnJR|UxRTN5LkeyNVgh|ryPMn[xV2FPT0WU
SCC-4MmfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF;NcJFKSzVyPUO3Mlc5PDNizszNMlLjV2FPT0WU
COLO-680NNHfuVWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGH3cppKSzVyPUO4MlI5QDVizszNNIX6eVdUSU6JRWK=
SK-MES-1MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1TlXWlEPTB;M{iuN|IyPSEQvF2=M2PDb3NCVkeHUh?=
SRMn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmrXTWM2OD1|OD61OFk2KM7:TR?=M2TRdXNCVkeHUh?=
LNCaP-Clone-FGCM4HHcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHi3SpJKSzVyPUO4MlU3OzdizszNNILwRZFUSU6JRWK=
SK-HEP-1MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWO4V|R7UUN3ME2zPE44QDJ{IN88US=>NFfRbmZUSU6JRWK=
BPH-1M3\KXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF7QRYlKSzVyPUO4Mlg{OjlizszNM4nzNHNCVkeHUh?=
NCI-H1755NIPpPYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{DFRWlEPTB;M{muOVgyPyEQvF2=NGDmZVRUSU6JRWK=
LXF-289NULx[Wp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M12zO2lEPTB;M{muPFA5PCEQvF2=NXn3ZpZqW0GQR1XS
SW1088MkPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTRyLkKxNFch|ryPMmn6V2FPT0WU
MOLT-4MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoriTWM2OD12MD6yPVAyKM7:TR?=NF7ZR3lUSU6JRWK=
AsPC-1MkTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{jrWmlEPTB;NECuOFU5OyEQvF2=NVHHNG1jW0GQR1XS
HOP-62MkXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRTRyLk[1Olgh|ryPNY\DSmxPW0GQR1XS
A172NYDVXXlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUPJR|UxRTRyLki1NVEh|ryPNEPB[YZUSU6JRWK=
SN12CMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3v0NmlEPTB;NECuPVM5PSEQvF2=NWe5eJB2W0GQR1XS
MDA-MB-231NFrBdo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3zudWlEPTB;NECuPVg6QCEQvF2=MWjTRW5ITVJ?
RPMI-2650MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY\JR|UxRTRzLkG1PVMh|ryPNEnuRo1USU6JRWK=
KYSE-140MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTRzLkixNlMh|ryPMYjTRW5ITVJ?
KINGS-1MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NG[1OY1KSzVyPUSyMlQ3QTdizszNMU\TRW5ITVJ?
HSC-3NFvVNYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1W3cmlEPTB;NEKuOlY3OSEQvF2=MoLNV2FPT0WU
PC-14NGH3[ZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3ixSWlEPTB;NEOuNVg5OiEQvF2=NV[zNGJxW0GQR1XS
COR-L105NIH3TmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX3JR|UxRTR|Lk[1NFIh|ryPNGjscWNUSU6JRWK=
BE-13NH;BVHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn;TTWM2OD12ND6yN|cyKM7:TR?=M4nrXHNCVkeHUh?=
NCI-H661NYnyd3lzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkTJTWM2OD12ND6yPVU5KM7:TR?=Ml7iV2FPT0WU
IST-MEL1NH7FboRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnPDTWM2OD12ND6zOVk6KM7:TR?=NHzVcnRUSU6JRWK=
HCC1806NWTmRVMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEe2O5RKSzVyPUS0MlU5PzNizszNNYfYc|Q5W0GQR1XS
COLO-800NXKzZVFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVnBcY9wUUN3ME20OE45PDV|IN88US=>NXKzclhGW0GQR1XS
IST-SL2NGXOfmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3raRmlEPTB;NEWuNVI1PyEQvF2=NIq4VZBUSU6JRWK=
8305CNF\xOFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M13SWmlEPTB;NEWuN|A6KM7:TR?=M3n0[3NCVkeHUh?=
UACC-62NFTDbYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoKwTWM2OD12Nj6yPFc2KM7:TR?=NV:5XFJqW0GQR1XS
COR-L23M365cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVvJR|UxRTR5LkG5PUDPxE1?M1z3R3NCVkeHUh?=
EFE-184NWDjUlF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3;BSWlEPTB;NEeuN|g5KM7:TR?=M1jTUXNCVkeHUh?=
DMS-114NFPuN|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NULCeoVHUUN3ME20O{41OTR7IN88US=>MmPZV2FPT0WU
KYSE-520M2iz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYXjN4dHUUN3ME20PE42OzF3IN88US=>NVnae3ZrW0GQR1XS
SNG-MNEDJW4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MU\JR|UxRTR7LkSzOEDPxE1?NW\WRlV2W0GQR1XS
A2058NWPUNXhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlrUTWM2OD12OT60PFg2KM7:TR?=NUTiWGhXW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

Protein kinase biochemical assays Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.

Cell Assay: [1]

Cell lines MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
Concentrations 0.02-0.8 μM
Incubation Time 3 days
Method For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.

Animal Study: [1]

Animal Models IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
Formulation 25 mM tartaric acid
Dosages 25 mg / kg and 75 mg / kg
Administration Orally administrated at once-daily oral dose for 14 days

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Mulvihill MJ, et al. Future Med Chem, 2009, 1(6), 1153-1171.

[2] McKinley ET, et al. Clin Cancer Res, 2011, 17(10), 3332-3340.

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02057380 Active, not recruiting Advanced Solid Tumors Astellas Pharma Global Development, Inc.|Astellas Pharma Inc April 2014 Phase 2
NCT02546544 Active, not recruiting Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research a  ...more University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01567384 Withdrawn Cancer|Neoplasms|Tumors Emory University|OSI Pharmaceuticals May 2012 Phase 1
NCT01560260 Completed Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma National Cancer Institute (NCI) March 2012 Phase 2

view more

Chemical Information

Download OSI-906 (Linsitinib) SDF
Molecular Weight (MW) 421.49
Formula

C26H23N5O

CAS No. 867160-71-2
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 84 mg/mL (199.29 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% PEG 400+0.5% Tween 80+5% Propylene glycol 30mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol

Frequently Asked Questions

  • Question 1
    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

    Answer: OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related IGF-1R Products

  • Picropodophyllin (PPP)

    Picropodophyllin (PPP) is a selective IGF-1R inhibitor with IC50 of 1 nM. Phase 1/2.

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • R428 (BGB324)

    R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).

  • BMS-536924

    BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.

  • NVP-AEW541

    NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.

  • NVP-ADW742

    NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.

  • GSK1904529A

    GSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.

  • BMS-754807

    BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

    Features:Muti-inhibitor of the IGR-1R/IR family.

  • AG-1024

    AG-1024 (Tyrphostin) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).

  • PQ 401

    PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Recently Viewed Items

Tags: buy OSI-906 (Linsitinib) | OSI-906 (Linsitinib) supplier | purchase OSI-906 (Linsitinib) | OSI-906 (Linsitinib) cost | OSI-906 (Linsitinib) manufacturer | order OSI-906 (Linsitinib) | OSI-906 (Linsitinib) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us